Eli Lilly and Company (NYSE:LLY) Stake Boosted by DeDora Capital Inc.

DeDora Capital Inc. grew its stake in shares of Eli Lilly and Company (NYSE:LLY) by 21.1% during the 1st quarter, HoldingsChannel reports. The fund owned 2,152 shares of the company’s stock after acquiring an additional 375 shares during the period. DeDora Capital Inc.’s holdings in Eli Lilly and Company were worth $1,674,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of LLY. Lipe & Dalton bought a new stake in Eli Lilly and Company in the fourth quarter worth $26,000. Thompson Investment Management Inc. bought a new stake in Eli Lilly and Company in the third quarter worth $27,000. Tidemark LLC bought a new stake in Eli Lilly and Company in the fourth quarter worth $29,000. Core Wealth Advisors Inc. boosted its holdings in Eli Lilly and Company by 188.2% in the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock worth $29,000 after purchasing an additional 32 shares in the last quarter. Finally, Legacy Financial Group LLC bought a new stake in Eli Lilly and Company in the third quarter worth $35,000. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Stock Performance

Shares of LLY traded down $20.94 during trading hours on Friday, reaching $734.97. 4,595,138 shares of the company traded hands, compared to its average volume of 2,629,045. The stock’s fifty day moving average is $761.06 and its 200 day moving average is $671.38. The stock has a market cap of $698.52 billion, a P/E ratio of 108.24, a price-to-earnings-growth ratio of 1.50 and a beta of 0.37. The company has a debt-to-equity ratio of 1.90, a quick ratio of 0.73 and a current ratio of 1.35. Eli Lilly and Company has a 1-year low of $419.80 and a 1-year high of $800.78.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Tuesday, April 30th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The firm had revenue of $8.77 billion during the quarter, compared to analyst estimates of $8.94 billion. During the same quarter in the prior year, the business posted $1.62 earnings per share. The company’s quarterly revenue was up 26.0% compared to the same quarter last year. Equities research analysts anticipate that Eli Lilly and Company will post 13.83 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently issued reports on LLY. Bank of America upped their price objective on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a report on Friday, March 1st. TheStreet upgraded shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. Cantor Fitzgerald restated an “overweight” rating and set a $885.00 price target (up from $815.00) on shares of Eli Lilly and Company in a report on Tuesday. Barclays upped their price target on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a report on Wednesday, February 7th. Finally, JPMorgan Chase & Co. upped their price target on shares of Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a report on Wednesday. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $757.95.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.